Why the study?
Does ECMO improve mortality in pediatric patients with pulmonary artery hypertension from noncongenital cardiac disease compared to non-ECMO therapy?
Does ECMO improve mortality in pediatric patients with pulmonary artery hypertension from noncongenital cardiac disease compared to non-ECMO therapy?
Answers are grounded in this paper and cite their sources.
This editorial highlights the high mortality and complication rates associated with ECMO in pediatric PAH, emphasizing the need for prospective studies to understand patient trajectories and optimize the timing of intervention.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wearden et al. (2016) conducted an editorial in Pulmonary artery hypertension (PAH) from noncongenital cardiac disease. Extracorporeal membrane oxygenation (ECMO) vs. Propensity-matched cohort not treated with ECMO was evaluated on Mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: